235 related articles for article (PubMed ID: 29696703)
1. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
[TBL] [Abstract][Full Text] [Related]
2. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Dytfeld D; Rosebeck S; Kandarpa M; Mayampurath A; Mellacheruvu D; Alonge MM; Ngoka L; Jasielec J; Richardson PG; Volchenboum S; Nesvizhskii AI; Sreekumar A; Jakubowiak AJ
Br J Haematol; 2015 Jul; 170(1):66-79. PubMed ID: 25824111
[TBL] [Abstract][Full Text] [Related]
5. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D; Luczak M; Wrobel T; Usnarska-Zubkiewicz L; Brzezniakiewicz K; Jamroziak K; Giannopoulos K; Przybylowicz-Chalecka A; Ratajczak B; Czerwinska-Rybak J; Nowicki A; Joks M; Czechowska E; Zawartko M; Szczepaniak T; Grzasko N; Morawska M; Bochenek M; Kubicki T; Morawska M; Tusznio K; Jakubowiak A; Komarnicki MA
Oncotarget; 2016 Aug; 7(35):56726-56736. PubMed ID: 27527861
[TBL] [Abstract][Full Text] [Related]
7. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
8. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
9. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
[TBL] [Abstract][Full Text] [Related]
10. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
11. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
[No Abstract] [Full Text] [Related]
12. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
13. Inside Haematologica: new concepts in the management of multiple myeloma.
Haematologica; 2002 Aug; 87(8):786-7. PubMed ID: 12161351
[No Abstract] [Full Text] [Related]
14. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
15. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
19. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
20. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
